A new therapeutic target for metastatic and resistant prostate cancers

December 05, 2018

A new combined therapy to fight the most aggressive and resistant prostate cancers. This is one of the conclusions reached by Prostate Cancer researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Álvaro Aytés. The team, which has just published its latest results in Nature Communications, also includes researchers from the Catalan Institute of Oncology, Columbia University in New York and the University of Bern in Switzerland.

The study identifies a new vulnerability in aggressive, metastatic prostate cancers that have become resistant to the hormonal therapies available today. Specifically, researchers showed that these tumors generate increasing levels of the NSD2 protein during tumor progression and acquisition of resistance to therapies. In addition, they were able to experimentally confirm that these tumors, in order to keep growing and spreading, are dependent on this protein. For these reasons, NSD2 represents an emerging therapeutic target against prostate cancer.

To achieve these results, researchers used a series of transgenic mice carrying mutations that are prevalent in prostate cancer patients. These mutations were only active in the cells of the prostatic epithelium of mice, as it happens in the vast majority of patients. Based on these models, once the mice developed cancer, cells from both primary prostate tumors and metastases were isolated, and patterns of gene expression analyzed. Thanks to the the use of bioinformatics tools, researchers identified candidate genes to be regarded as vulnerabilities in these aggressive tumors. Following this experimental approach, the team identified those factors that, in a differential way, are present in malignancy and metastasis. NSD2 is one of the main examples.

NSD2 is a protein with enzymatic activity that induces chemical modifications (specifically, methyl groups) to other proteins in charge of providing structural support to DNA strands, called histones. This process of chemical modification of DNA, or epigenetics, is often associated with the control of gene expression. Specifically, the modifications in histones caused by NSD2 result in a relaxation in the levels of compaction of the DNA strands (known as chromatin), triggering the expression of a set of genes with tumorigenic potential.

One of the main hypotheses of the researchers behind this study is that the activation of these genes - caused by NSD2 - is responsible for the development of resistance to the chemotherapeutic treatments usually administered to prostate cancer patients. In this sense, researchers are working with molecules capable of inhibiting the function of NSD2 and, therefore, decrease the malignancy of prostate tumors in mice. In fact, the study has shown that the pharmacological inhibition of NSD2 results in an increase in the survival of the experimental model, a decrease in metastasis and a reduction in the size of the tumors.

Thanks to these results, researchers conclude that the inhibition of NSD2 could lead to re-sensitization of prostate tumors that show resistance to the usual antiandrogenic treatments. This may eventually lead to the implementation of a combined therapy that would include the administration of an NSD2 inhibitor drug together with conventional antiandrogenic drugs.

IDIBELL-Bellvitge Biomedical Research Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.